Literature DB >> 7737235

Antibiotic activity in serum following single and repeated oral administration of sodium fusidate in volunteers.

P Munkholm1, H Hey, S N Rasmussen, P B Johansen.   

Abstract

The pharmacokinetics of antibiotic activity were investigated in 10 healthy, female volunteers receiving a single oral dose of sodium fusidate (500 mg) followed after 48 h by repeated oral dosing of 250 mg b.i.d. for 5 consecutive days. By use of turbidimetry, drug-related antibiotic activity in serum was determined and expressed as fusidic acid equivalents. After a single dose and repeated dosing, the peak concentrations were (mean +/- SE): 30 +/- 3 micrograms/ml and 27 +/- 3 micrograms/ml, respectively (NS), and the trough concentration at steady state was 8.4 +/- 1.8 micrograms/ml. The experimental and predicted accumulation ratios were 2.1 +/- 0.1 versus 1.6 +/- 0.2, respectively (P < 0.16). By use of a model independent method, the terminal elimination half-lives were estimated to be 11 +/- 1 h and 13 +/- 2 h after a single dose and repeated doses, respectively (NS). The total clearances of antibiotic activity were 2.0 +/- 0.4 l/h after a single dose and 1.6 +/- 0.2 l/h after repeated doses (P < 0.11). Model dependent pharmacokinetic parameters were also obtained by fitting a two-compartment open model to the median serum concentrations which, with respect to half-life and clearance, gave values close to those observed by use of the model independent approach. Safety-wise, biochemical parameters were within the normal range. However, a statistically significant increase in ASAT and a decrease in leucocytes were observed. The tolerability of the drug was good and only minor adverse events were reported.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7737235     DOI: 10.1007/BF03188860

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  Fucidin: a new orally active antibiotic.

Authors:  W GODTFREDSEN; K ROHOLT; L TYBRING
Journal:  Lancet       Date:  1962-05-05       Impact factor: 79.321

2.  Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation.

Authors:  A M Taburet; J Guibert; M D Kitzis; H Sorensen; J F Acar; E Singlas
Journal:  J Antimicrob Chemother       Date:  1990-02       Impact factor: 5.790

3.  Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers.

Authors:  A P MacGowan; M A Greig; J M Andrews; D S Reeves; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

Review 4.  The pharmacokinetics of fusidic acid.

Authors:  D S Reeves
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

5.  Estimating the accumulation of drugs.

Authors:  W A Colburn
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

6.  The disposition of sodium fusidate in man.

Authors:  R Wise; M Pippard; M Mitchard
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

7.  On the metabolism of fusidic acid in man.

Authors:  W O Godtfredsen; S Vangedal
Journal:  Acta Chem Scand       Date:  1966

8.  Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.

Authors:  E Langholz; J Brynskov; K Bendtzen; M Vilien; V Binder
Journal:  Aliment Pharmacol Ther       Date:  1992-08       Impact factor: 8.171

9.  Fusidic acid for Behçet's colitis: a novel approach to T-cell specific immunosuppressive therapy.

Authors:  E Langholz; J Brynskov; L G Freund; K Bendtzen
Journal:  Dan Med Bull       Date:  1991-06

10.  Concentrations of fusidic acid, cloxacillin, and cefamandole in sera and atrial appendages of patients undergoing cardiac surgery.

Authors:  M G Bergeron; D Desaulniers; C Lessard; M Lemieux; J P Després; J Métras; G Raymond; G Brochu
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

View more
  2 in total

1.  Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.

Authors:  Jürgen B Bulitta; Olanrewaju O Okusanya; Alan Forrest; Sujata M Bhavnani; Kay Clark; J Gordon Still; Prabhavathi Fernandes; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

2.  Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.

Authors:  Anshul Gupta; Jennifer J Harris; Jianrong Lin; James P Bulgarelli; Bruce K Birmingham; Scott W Grimm
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.